MIGENIX Initiates Enrollment in Phase IIb Hepatitis C Clinical Study of Celgosivir in Combination with PEGETRON(TM)
VANCOUVER and SAN DIEGO, Nov. 22 /PRNewswire-FirstCall/ - MIGENIX Inc.
(TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, has initiated enrollment in a Phase IIb combination therapy clinical trial of celgosivir (MX-3253), supported in part through an
agreement with Schering-Plough. Celgosivir is an orally administered, first-in-class alpha glucosidase 1 inhibitor, in development for the treatment of chronic hepatitis C virus (HCV) infections. Results of the study are
anticipated in mid-calendar 2006.
Jim DeMesa, M.D., President and CEO of MIGENIX stated, "With the large market potential and unmet need in current hepatitis C treatment, celgosivir is an important component of our value proposition in the short-term. Based on
its strong demonstration of synergy in non-clinical studies to date, celgosivir shows great promise as part of a combination therapy approach to improving the success of treatment for patients suffering from chronic hepatitis C infections."
About MX-3253 and the Phase IIb Combination Study
MX-3253 (celgosivir) is an alpha-glucosidase I inhibitor and is currently the only oral anti-HCV drug in clinical development that acts through host- directed glycosylation. In preclinical studies, celgosivir has demonstrated strong synergy with interferon-alpha with and without ribavirin and has the potential to be included as part of a combination therapeutic approach to improve efficacy and/or tolerability. A recently completed Phase IIa monotherapy study demonstrated that celgosivir was well tolerated with some evidence of antiviral activity in treatment-naive chronic HCV patients.
The Phase IIb combination study of MX-3253 is a
randomized, multi-center, active-controlled,
12 week evaluation of MX-3253 in three treatment arms of up
to 20 chronic HCV "non-responder" patients each:
celgosivir plus peginterferon alfa-2b plus ribavirin (3-way combination);
celgosivir plus peginterferon alfa-2b (2-way combination);
and placebo plus peginterferon alfa-2b plus ribavirin (control).
An agreement was completed in July with Schering-Plough
Corporation where they are contributing (a) the supply of PEGETRON(TM) (peginterferon alfa-2b powder for solution plus ribavirin 200 mg capsules) and (b) certain technical and laboratory support and other services for the study.
In addition, the agreement grants Schering-Plough limited periods of exclusivity for data review of clinical trial results and for the negotiation of a license agreement.
Patients for the Phase IIb study will be selected based on having genotype 1 chronic HCV and having failed to respond to pegylated alpha interferon plus ribavirin therapy (non-responders).
Today, there are very limited treatment options for the approximately 50% of HCV patients who have failed treatment with the current standard of care, pegylated interferon plus
ribavirin.
About HCV
HCV, the most common chronic blood-borne infection in the United States, causes inflammation of the liver and may progress to more serious complications such as cirrhosis of the liver, liver cancer and death.
Approximately 2.7 million people in the United States are chronically infected with HCV, and the Centers for Disease Control and Prevention (CDC) estimates that by the year 2010, the number of deaths attributed annually to HCV could
surpass that due to HIV/AIDS in the US. Worldwide, the World Health Organization estimates that 170 million individuals carry chronic HCV infection, with 3 to 4 million new infections each year.
Therapy for HCV currently employs a drug combination approach, which is anticipated to continue in the future. The current standard of care for chronic hepatitis C is pegylated interferon combined with ribavirin, which fails to provide a satisfactory outcome for approximately 50% of patients
infected with HCV genotype 1. In addition, these drugs can cause significant side effects that limit tolerance to therapy, or a frequent lack of sustained treatment response.
About MIGENIX
MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases.
The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C infections (Phase
II),
the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I)
and the treatment of acne (Phase II).
MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at
migenix.com.
"Jim DeMesa"
------------
James M. DeMesa, M.D.
President & CEO
CONTACTS
Jonathan Burke Dian Griesel, Ph.D.
MIGENIX Inc. Investor Relations Group
Tel: (604) 221-9666 Tel: (212) 825-3210
Extension 241 Theproteam@aol.com
jburke@migenix.com
prnewswire.com |
